Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis.

Rovati, Gianenrico; Contursi, Annalisa; Bruno, Annalisa; Tacconelli, Stefania; Ballerini, Patrizia; Patrignani, Paola

Metastasis requires that cancer cells survive in the circulation, colonize distant organs, and grow. Despite platelets being central contributors to hemostasis, leukocyte trafficking during inflammation, and vessel stability maintenance, there is significant evidence to support their essential role in supporting metastasis through different mechanisms. In addition to their direct interaction with cancer cells, thus forming heteroaggregates such as leukocytes, platelets release molecules that are necessary to promote a disseminating phenotype in cancer cells via the induction of an epithelial–mesenchymal-like transition. Therefore, agents that affect platelet activation can potentially restrain these prometastatic mechanisms. Although the primary adhesion of platelets to cancer cells is mainly independent of G protein-mediated signaling, soluble mediators released from platelets, such as ADP, thromboxane (TX) A2, and prostaglandin (PG) E2, act through G protein-coupled receptors (GPCRs) to cause the activation of more additional platelets and drive metastatic signaling pathways in cancer cells. In this review, we examine the contribution of the GPCRs of platelets and cancer cells in the development of cancer metastasis. Finally, the possible use of agents affecting GPCR signaling pathways as antimetastatic agents is discussed.

METASTASIS; BLOOD platelets; PLATELET aggregation inhibitors; CARCINOGENESIS; BLOOD platelet activation; CANCER cells; G protein coupled receptors

Cells (2073-4409), 2022, Vol 11, Issue 4, p725

2073-4409

Academic Journal

10.3390/cells11040725